Hamilton Depression Rating Scale (HAM-D17): Scoring, MADRS, BDI-II, and FDA Remission Criteria

The Hamilton Depression Rating Scale (HAM-D or HDRS), published by Max Hamilton at the University of Leeds in 1960 (Journal of Neurology, Neurosurgery, and Psychiatry), is the foundational clinician-administered observer rating scale for quantifying depressive symptom severity in psychiatry clinical trials. In regulatory drug development for Major Depressive Disorder (MDD), the 17-item version (HAM-D17) and the 10-item Montgomery-Åsberg Depression Rating Scale (MADRS) serve as the two primary clinician-reported outcome (ClinRO) efficacy endpoints accepted by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), often supplemented by the self-report 21-item Beck Depression Inventory-II (BDI-II).

HAM-D17 Item Structure, Scoring Rules, and the SIGH-D Interview Guide

Although Max Hamilton’s original 1960 paper listed 21 items, Hamilton explicitly specified that only the first 17 items (HAM-D17) should be summed to calculate total depressive severity—because Items 18–21 (diurnal variation, depersonalization/derealization, paranoid symptoms, and obsessional/compulsive symptoms) either characterize subtype patterns or occur too infrequently to reflect linear severity. (Later 21-item, 24-item, and 28-item expansions added helplessness, hopelessness, worthlessness, hypersomnia, and atypical weight gain.)

On the standard HAM-D17 (total score range 0–52), items are rated across two different ordinal scales:

• Nine Items Scored 0–4 (0 = absent, 1 = doubtful/mild, 2 = mild/moderate, 3 = moderate/severe, 4 = severe/incapacitating):
  • Item 1: Depressed mood (sadness, hopeless, helpless, worthless)
  • Item 2: Feelings of guilt
  • Item 3: Suicide
  • Item 7: Work and activities (anhedonia and functional impairment)
  • Item 8: Retardation (psychomotor slowing of thought and speech)
  • Item 9: Agitation
  • Item 10: Anxiety — psychic
  • Item 11: Anxiety — somatic (gastrointestinal, palpitations, hyperventilation, sweating)
  • Item 15: Hypochondriasis
• Eight Items Scored 0–2 (0 = absent, 1 = mild/doubtful, 2 = clearly present/severe):
  • Item 4: Insomnia — early (difficulty falling asleep)
  • Item 5: Insomnia — middle (restlessness/disturbed night sleep)
  • Item 6: Insomnia — late (waking in early hours and unable to return to sleep)
  • Item 12: Somatic symptoms — gastrointestinal (loss of appetite)
  • Item 13: Somatic symptoms — general (heaviness in limbs, back, or head; loss of energy)
  • Item 14: Genital symptoms (loss of libido, menstrual disturbances)
  • Item 16: Loss of weight (rated by history 0–2 or weekly weight measurement)
  • Item 17: Insight (acknowledgment of being depressed and ill)

To standardize inter-rater reliability across multicenter trials, Janet B. W. Williams (Archives of General Psychiatry, 1988) developed the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D), which provides standardized semi-structured prompts and anchor definitions for a 1-week recall window. Standard Zimmerman et al. (2013) and American Psychiatric Association severity bands for HAM-D17 are: 0–7 (no depression / clinical remission), 8–16 (mild depression), 17–23 (moderate depression), and ≥24 (severe depression). A 6-item melancholia subscale (HAM-D6, Bech et al., 1975: Items 1, 2, 7, 8, 10, 13) is also frequently analyzed as a unidimensional secondary endpoint.

How Does the 17-Item HAM-D17 Compare with the 10-Item Montgomery-Åsberg Depression Rating Scale (MADRS)?

Stuart A. Montgomery and Marie Åsberg published the 10-item Montgomery-Åsberg Depression Rating Scale (MADRS) in 1979 (British Journal of Psychiatry) after analyzing a 65-item Comprehensive Psychopathological Rating Scale (CPRS) to isolate the 10 symptoms most sensitive to antidepressant treatment change.

Every item on the MADRS (total score range 0–60) is scored on a uniform 7-point ordinal scale (0–6), with explicit behavioral anchor definitions at 0, 2, 4, and 6 (and intermediate ratings 1, 3, and 5 assigned when severity falls between anchors). In clinical trials, raters administer the MADRS using the SIGMA (Structured Interview Guide for the MADRS) developed by Williams and Kobak (2008). The 10 MADRS items are:

1. Apparent sadness
2. Reported sadness
3. Inner tension
4. Reduced sleep
5. Reduced appetite
6. Concentration difficulties
7. Lassitude
8. Inability to feel (anhedonia / emotional numbness)
9. Pessimistic thoughts
10. Suicidal thoughts

Why Is the 10-Item MADRS (0–60) More Sensitive to Treatment Change in Core Affective Symptoms Than HAM-D17?

Psychometric and item-response theory (Item Response Theory) evaluations demonstrate three structural reasons why the MADRS frequently exhibits higher responsiveness (standardized effect size) to modern selective serotonin/norepinephrine reuptake inhibitors (SSRIs/SNRIs) and rapid-acting antidepressants than the HAM-D17:

1. Heavy Somatic and Sleep Weighting in HAM-D17: Three separate HAM-D17 items measure insomnia (early, middle, and late, up to 6 points total) and three items measure somatic/gastrointestinal symptoms and weight loss (up to 6 points). Sedating tricyclic antidepressants or adjunctive hypnotics can improve sleep and appetite scores within days without resolving core depressed mood, artificially lowering HAM-D17 scores. Conversely, activating antidepressants (such as bupropion or SSRIs) can cause transient early insomnia, gastrointestinal nausea, or sexual dysfunction (Items 4–6, 11, 12, 14), blunting apparent HAM-D17 improvement even when core mood improves.
2. Uniform 0–6 Scaling Across Core Mood Items: On the HAM-D17, items scored 0–4 and 0–2 contribute unequally to total variance, and multidimensional factor analyses show HAM-D17 splits into 3–4 separate factors. On the MADRS, all 10 items share a 0–6 range focused tightly on core affective, cognitive, and anhedonic psychopathology.
3. Separation of Observed vs. Reported Sadness: The MADRS separates clinician-observed nonverbal affect (Item 1: Apparent sadness) from subjective verbal report (Item 2: Reported sadness), increasing discriminative granularity in severe depression.

FDA and EMA Remission Cutoffs, Response Criteria, and the BDI-II

Under the FDA Guidance for Industry: Major Depressive Disorder — Developing Drugs for Treatment (2018) and EMA depression trial guidelines, Phase II/III registration trials evaluate continuous change from baseline alongside two categorical responder endpoints—while often capturing patient-perceived severity via ePRO in clinical trials using the 21-item Beck Depression Inventory-II (BDI-II) (Beck, Steer, & Brown, 1996) or PHQ-9 inside electronic clinical outcome assessment (eCOA) systems:

Instrument	Rater & Format	Total Range	Severity Bands	Clinical Trial Response & Remission Criteria
HAM-D17 / HDRS-17 (Hamilton, 1960; SIGH-D, 1988)	Clinician-rated (ClinRO) via SIGH-D interview; 9 items 0–4, 8 items 0–2	0–52	0–7 Normal 8–16 Mild 17–23 Moderate ≥24 Severe	Response: ≥50% reduction from baseline Remission: Total score ≤7
MADRS (Montgomery & Åsberg, 1979; SIGMA, 2008)	Clinician-rated (ClinRO) via SIGMA interview; 10 items rated 0–6	0–60	0–6 Normal 7–19 Mild 20–34 Moderate ≥35 Severe	Response: ≥50% reduction from baseline Remission: Total score ≤10 (or ≤12 in select protocols)
BDI-II (Beck, Steer, & Brown, 1996)	Patient self-report (PRO); 21 items rated 0–3 over a 2-week recall window	0–63	0–13 Minimal 14–19 Mild 20–28 Moderate 29–63 Severe	Response: ≥50% reduction from baseline Remission: Total score ≤9 or ≤12

In pediatric and adolescent trials, investigators substitute age-validated scales such as the Children’s Depression Rating Scale-Revised (CDRS-R) or self-report RCADS (Revised Child Anxiety and Depression Scale), whereas geriatric studies use the Geriatric Depression Scale (GDS-15 / GDS-30) to avoid somatic confounding.

Frequently Asked Questions

How does the clinician-administered 17-item Hamilton Depression Rating Scale (HAM-D17 / HDRS-17) compare with the 10-item Montgomery-Åsberg Depression Rating Scale (MADRS)?

The HAM-D17 (0–52 total score) uses mixed item scaling (nine items rated 0–4 and eight items rated 0–2) with substantial weighting on somatic anxiety, gastrointestinal symptoms, and three stages of insomnia. The MADRS (0–60 total score) uses a uniform 0–6 scale across 10 core affective, cognitive, and anhedonic items, making it shorter to administer via the SIGMA guide and less confounded by medication side effects.

What are the FDA and EMA standard remission cutoffs (HAM-D17 ≤ 7 and MADRS ≤ 10) and response criteria (≥50% reduction) in antidepressant trials?

In FDA and EMA registration trials for Major Depressive Disorder, clinical response is defined as a ≥50% reduction in total baseline score on the HAM-D17 or MADRS, whereas symptomatic remission is defined as achieving an endpoint score of HAM-D17 ≤ 7 or MADRS ≤ 10.

Why is the 10-item MADRS (0–60) more sensitive to treatment change in core affective symptoms than HAM-D17?

The MADRS was specifically constructed by selecting the 10 CPRS items most responsive to antidepressant therapy, using 7-point (0–6) ratings on core mood, inner tension, concentration, lassitude, and inability to feel, while avoiding the heavy somatic, sleep, and sexual side-effect items that dilute treatment signal on the HAM-D17.